Cuprina Holdings (Cayman) Ltd. has appointed Dr. Ronald A. Sherman as Medical and Scientific Director, effective September 2025. Dr. Sherman, known for his work in medical maggot therapies, will provide clinical leadership and guidance on bio-therapeutics, and assist in developing a training framework for clinicians. Cuprina is updating its FDA submission for Lucilia cuprina maggots, aiming to secure a second U.S. FDA clearance for maggot debridement therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.